Pitt Street Research

Dimerix

Dimerix

Dimerix (ASX:DXB)

Dimerix is a drug discovery company that can identify important drug targets called G Protein-Coupled Receptors. Dimerix’s lead DMX-200 candidate, a combination of irbesartan and propagermanium, is in Phase 2 in kidney disease.